The global diabetes market has entered a period of accelerated transformation. Breakthroughs in continuous glucose monitoring, automated insulin delivery, and GLP-1 receptor agonist therapies have shifted diabetes management from reactive treatment toward proactive, personalized care. At the same time, rising prevalence — with approximately 148 million adult diabetics in China alone, 66 million in Europe, and an estimated 27.6% of U.S. diabetics still undiagnosed — underscores the scale of unmet need that continues to pull investment, innovation, and commercial attention into this space.
According to BCC Research, the global market for latest development, product innovations, and treatments for diabetes was valued at $107.5 billion in 2024 and is projected to reach $237.4 billion by 2031, growing at a compound annual growth rate of 12.0% between 2026 and 2031. That trajectory reflects compounding demand across pharmaceuticals, glucose monitoring device technologies, and insulin delivery device technologies — each segment reinforcing the others as integrated digital diabetes management becomes the standard of care.
The companies driving this growth span pharmaceutical giants reshaping metabolic disease treatment to specialized device makers redefining how patients monitor and deliver insulin. The following sections examine the leading segments and regional dynamics shaping the market, then profile the ten companies at the center of it.
Among the three primary product categories, diabetic pharmaceuticals dominate the commercial landscape. Injectable therapies are the fastest-growing sub-segment within pharmaceuticals, propelled by surging demand for GLP-1 receptor agonists such as Ozempic and Mounjaro. North American injectable therapies alone reached $38.3 billion in 2026 and are growing at a 16.1% CAGR. Oral antidiabetic drugs represent a more mature but still substantial segment at $16.7 billion in North America in 2026, sustaining moderate growth through established SGLT2 and DPP-4 inhibitor classes. Within monitoring, continuous glucose monitoring systems stand out as the single fastest-growing sub-segment across all device categories, reaching $15.8 billion in 2026 at a 13.5% CAGR globally, driven by sensor accuracy improvements, smartphone integration, and expanding insurance and NHS reimbursement.
North America commands the largest regional share at approximately 43.7% of the global market in 2024, underpinned by high diabetes prevalence, strong reimbursement coverage for CGM and insulin delivery systems, and the world's largest GLP-1 agonist market. Europe holds second position at roughly 20.8%, supported by 66 million diabetes patients and the highest concentration of type 1 diabetes globally. Asia-Pacific, at approximately 18.4%, is the fastest-growing major region — China's market is projected to reach $19.6 billion by 2031 at a 16.4% CAGR, driven by government chronic disease programs and the world's largest diabetic population. Among individual country markets in Europe, Germany leads at $9.9 billion in 2026 growing at 12.7% CAGR, while the United Kingdom follows at $6.7 billion growing at 13.7% CAGR, supported by NHS CGM expansion and an artificial pancreas rollout for pregnant women with type 1 diabetes.
• Headquarters: Abbott Park, Illinois, U.S.
• Founded: 1888
• Revenue: $44,328 million (FY2025)
• Employees: 115,000
• Focus: Medical devices, diagnostics, nutritional products, established pharmaceuticals
Abbott is one of the most broadly positioned companies in the diabetes market, anchored by its FreeStyle Libre CGM product line. The company is actively integrating Libre data with Epic Systems' electronic health record platform to improve clinical workflows and has partnered with Tandem Diabetes Care to link its upcoming dual glucose-ketone sensor with integrated insulin delivery solutions. A collaboration with Ypsomed and CamDiab to incorporate the sensor into the mylife Loop automated insulin delivery system reflects Abbott's push toward closed-loop diabetes management.
• Headquarters: San Diego, California, U.S.
• Founded: 1999
• Revenue: $4,662 million (FY2025)
• Employees: 11,100
• Focus: Continuous glucose monitoring systems, over-the-counter glucose biosensors, AI-powered digital health
Dexcom is a pure-play CGM company with a strong hold on the insulin-dependent patient segment and a growing presence in broader metabolic health monitoring. The company achieved 16% revenue growth in FY2025 on the back of strong Dexcom G7 adoption and international expansion. Its Stelo over-the-counter biosensor, enhanced in 2026 with AI-powered smart meal logging and personalized daily insights, extends its reach beyond clinical diabetes management. R&D investment at approximately 13% of total revenue signals continued commitment to platform innovation.
• Headquarters: Parsippany, New Jersey, U.S.
• Founded: 2022
• Revenue: $1,080.4 million (FY2025)
• Employees: 1,850
• Focus: Insulin delivery devices, pen needles, insulin syringes, safety injection devices, contract manufacturing
Embecta Corp. operates as a focused insulin delivery device company following its separation from BD. In 2024, the company received FDA 510(k) clearance for a disposable insulin patch pump with a 300-unit reservoir, designed specifically for people with type 2 diabetes who require higher insulin doses — a meaningful clinical distinction from most existing patch pump offerings. Embecta maintains manufacturing in Ireland, the U.S., and China, and distributes products to healthcare providers and patients across more than 100 countries.
• Headquarters: Basel, Switzerland
• Founded: 1896
• Revenue: $74,221.1 million (FY2025)
• Employees: 103,249
• Focus: Pharmaceuticals, diagnostics, glucose monitoring (Accu-Chek), insulin delivery, digital diabetes management (mySugr)
Roche operates across the full diabetes management chain, from central laboratory diagnostics to point-of-care glucose monitoring and digital platforms. The company launched the Accu-Chek SmartGuide CGM in the Middle East — the region's first AI-enabled system featuring predictive glucose notifications — and received CE Mark for it in 2024. Roche is investing $550 million by 2030 to build out U.S. manufacturing capacity for CGM systems. Its partnership with Respiree to integrate monitoring solutions across the APAC region further extends its digital diabetes footprint.
• Headquarters: Acton, Massachusetts, U.S.
• Founded: 2000
• Revenue: $2,708.1 million (FY2025)
• Employees: 5,400
• Focus: Omnipod tubeless insulin delivery systems, drug delivery
Insulet's Omnipod platform has become the reference point for tubeless, wearable insulin delivery. In 2024, the company secured FDA clearance for Omnipod 5 for adults with type 2 diabetes, making it the first automated insulin delivery system approved for both type 1 and type 2 indications. Insulet has expanded Omnipod 5 into markets across Italy, Scandinavia, France, the Netherlands, and the Middle East. CGM sensor integration covers both Dexcom G7 and Abbott FreeStyle Libre 2 Plus, and its global user base has grown to more than 600,000 customers.
• Headquarters: Indianapolis, Indiana, U.S.
• Founded: 1876
• Revenue: $65,179 million (FY2025)
• Employees: 50,000
• Focus: Diabetes care, GLP-1 and GIP therapies, oncology, immunology, neuroscience
Lilly has become one of the defining forces in the GLP-1 and GIP receptor agonist space. Mounjaro (tirzepatide), its dual GIP/GLP-1 agonist, nearly doubled revenue to $23 billion in FY2025, and Mounjaro together with Zepbound contributed 56% of total company revenue. Lilly is now advancing orforglipron, a candidate oral GLP-1 receptor agonist for type 2 diabetes and obesity that could become the first approved oral medication in its class by end of 2026. R&D spending reached $13.3 billion in FY2025, sustaining a broad pipeline across metabolic and other disease areas.
• Headquarters: Galway, Ireland
• Founded: 1949
• Revenue: $33,537 million (FY2024)
• Employees: 95,000
• Focus: Cardiovascular, medical surgical, neuroscience, diabetes
Medtronic's diabetes business has undergone a structural change, spinning off as the standalone company MiniMed and beginning to trade on Nasdaq in March 2026. Before the separation, Medtronic secured CE Mark for the MiniMed 780G hybrid closed-loop system across broader patient populations in Europe and received FDA approval for the Simplera Sync sensor and InPen app. The company has been managing tariff-related cost pressures estimated at up to $185 million in additional expenses in fiscal year 2026, a challenge common to semiconductor-dependent medical device manufacturers.
• Headquarters: Bagsværd, Denmark
• Founded: 1923
• Revenue: $46,792.3 million (FY2025)
• Employees: 69,505
• Focus: GLP-1 receptor agonists, insulin portfolio, diabetes and obesity care, rare diseases, advanced injection devices
Novo Nordisk sits at the center of the GLP-1 revolution. The company secured EMA approval for an updated cardiovascular benefits label for Rybelsus (oral semaglutide), making it the first oral GLP-1 receptor agonist in the EU with demonstrated heart benefits following the SOUL trial. It launched Awiqli (insulin icodec), the world's first once-weekly basal insulin, across Canada, the EU, Switzerland, Japan, Australia, and China. To extend its next-generation pipeline, Novo Nordisk licensed UBT251, a GLP-1/GIP/glucagon triple agonist, from United Biotechnology for $200 million upfront and up to $1.8 billion in milestone payments. R&D investment reached $7,878.7 million in 2025.
• Headquarters: Germantown, Maryland, U.S.
• Founded: 1996
• Revenue: $35.3 million (FY2025)
• Employees: 130
• Focus: Implantable continuous glucose monitoring systems
Senseonics occupies a distinctive position in the CGM market through its long-duration implantable sensor technology. The company received FDA clearance for Eversense 365 — the world's first one-year implantable CGM — in 2024 and obtained European CE Mark in 2026. A commercial development agreement with Sequel Med Tech integrates Eversense 365 with the Twiist automated insulin delivery platform, creating the first year-long AID-compatible CGM system. A distribution agreement with Ascensia Diabetes Care is designed to accelerate international accessibility for the Eversense platform.
• Headquarters: Ingelheim am Rhein, Germany
• Founded: 1885
• Revenue: $31,387 million (FY2025)
• Employees: 54,300
• Focus: Human pharma, diabetes therapeutics (Jardiance/empagliflozin)
Boehringer Ingelheim ranks third globally in diabetes therapies, built largely on the commercial performance of Jardiance (empagliflozin), its SGLT2 inhibitor, which recorded sales of $9,936 million in FY2025. The company's position reflects sustained demand for established oral antidiabetic drug classes alongside the GLP-1 agonist surge. Boehringer Ingelheim invested $7,185 million in R&D in FY2025 and operates across the Americas, Europe, Asia, Australia, and Africa, with the Americas as its primary business region. As a privately held company, it maintains greater strategic flexibility than publicly listed peers.
The diabetes market presents one of the clearest growth stories in healthcare: rising global prevalence, widening treatment eligibility through GLP-1 therapies, and rapid technology adoption in glucose monitoring and insulin delivery are compounding simultaneously. The companies profiled here reflect that breadth — from pharmaceutical leaders commercializing the next generation of metabolic therapies to device specialists engineering implantable sensors and fully automated insulin delivery systems.
What distinguishes the current phase of market development is the degree of integration between previously separate product categories. CGM data now flows into insulin pumps, smart pens, EHR platforms, and AI-powered decision support tools. That convergence rewards companies with platform strategies and interoperability agreements, and it creates meaningful barriers for competitors entering any single category in isolation. The $237.4 billion market projected for 2031 will be shaped by those who can connect the dots across monitoring, delivery, and therapy.
Consider becoming a member of the BCC Research library and gain access to our full catalog of market research reports in your industry. Not seeing what you are looking for? We offer custom solutions too, including our new product line: Custom Intelligence Services.
Contact us today to find out more.